300294 博雅生物
已收盘 10-30 15:00:00
资讯
新帖
简况
博雅生物（300294）2026年三季报简析：净利润同比下降81.82%
证券之星 · 11:51
博雅生物（300294）2026年三季报简析：净利润同比下降81.82%
博雅生物(300294)10月9日股东户数3.22万户，较上期减少0.51%
证券之星 · 10-30 19:26
博雅生物(300294)10月9日股东户数3.22万户，较上期减少0.51%
图解博雅生物三季报：第三季度单季净利润同比下降90.52%
证券之星 · 10-30 02:34
图解博雅生物三季报：第三季度单季净利润同比下降90.52%
华润医药：华润博雅生物前三季度净利润6058.83万元 同比减少82.34%
同花顺 · 10-29 17:22
华润医药：华润博雅生物前三季度净利润6058.83万元 同比减少82.34%
博雅生物：重点聚焦流程优化、费用管控、提升组织运营效率等推进降本增效落地落实
证券之星 · 10-27
博雅生物：重点聚焦流程优化、费用管控、提升组织运营效率等推进降本增效落地落实
股市必读：博雅生物（300294）10月23日董秘有最新回复
证券之星 · 10-26
股市必读：博雅生物（300294）10月23日董秘有最新回复
博雅生物：公司系华润集团大健康板块的血液制品平台
证券之星 · 10-23
博雅生物：公司系华润集团大健康板块的血液制品平台
股市必读：博雅生物（300294）10月20日董秘有最新回复
证券之星 · 10-21
股市必读：博雅生物（300294）10月20日董秘有最新回复
博雅生物：持续聚焦营销、研发、国际化、采浆等方面细化关键举措
证券之星 · 10-20
博雅生物：持续聚焦营销、研发、国际化、采浆等方面细化关键举措
股市必读：博雅生物（300294）10月16日董秘有最新回复
证券之星 · 10-19
股市必读：博雅生物（300294）10月16日董秘有最新回复
博雅生物：公司不存在上述事项
证券之星 · 10-16
博雅生物：公司不存在上述事项
博雅生物：公司2026年10月09日含信用账户合并名册的股东人数为32,186户
证券之星 · 10-16
博雅生物：公司2026年10月09日含信用账户合并名册的股东人数为32,186户
股市必读：博雅生物新发布《公司第八届董事会第二十三次会议决议公告》
证券之星 · 10-12
股市必读：博雅生物新发布《公司第八届董事会第二十三次会议决议公告》
股市必读：博雅生物新发布《公司第八届董事会第二十三次会议决议公告》
证券之星 · 10-09
股市必读：博雅生物新发布《公司第八届董事会第二十三次会议决议公告》
博雅生物（300294）披露召开2026年第三次临时股东会的通知，10月08日股价下跌1.87%
证券之星 · 10-08
博雅生物（300294）披露召开2026年第三次临时股东会的通知，10月08日股价下跌1.87%
博雅生物：公司持续深化战略实现途径
证券之星 · 09-30
博雅生物：公司持续深化战略实现途径
博雅生物：致力于成为国内乃至世界一流血液制品企业
证券之星 · 09-30
博雅生物：致力于成为国内乃至世界一流血液制品企业
股市必读：博雅生物（300294）9月23日董秘有最新回复
证券之星 · 09-24
股市必读：博雅生物（300294）9月23日董秘有最新回复
博雅生物：以做优做强主业、提升经营质量作为市值管理的核心措施
证券之星 · 09-23
博雅生物：以做优做强主业、提升经营质量作为市值管理的核心措施
博雅生物：截至目前，公司暂无回购、大股东增持等事项
证券之星 · 09-18
博雅生物：截至目前，公司暂无回购、大股东增持等事项
加载更多
公司概况
公司名称：
华润博雅生物制药集团股份有限公司
所属行业：
医药制造业
上市日期：
2012-03-08
主营业务：
华润博雅生物制药集团股份有限公司的主营业务是血液制品的研发、生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白（pH4）、凝血因子。公司获得了国家“863计划”项目、江西省重大研发专项等20多项政府专项，拥有各类专利200余项，多次荣膺省、市科学技术奖和优秀新产品奖。
发行价格：
25.00
{"stockData":{"symbol":"300294","market":"SZ","secType":"STK","nameCN":"博雅生物","latestPrice":13.63,"timestamp":1793343819000,"preClose":13.87,"halted":0,"volume":4804703,"delay":0,"changeRate":-0.0173,"floatShares":504000000,"shares":504000000,"eps":-0.3331,"marketStatus":"已收盘","change":-0.24,"latestTime":"10-30 15:00:00","open":13.56,"high":13.94,"low":13.44,"amount":65727700,"amplitude":0.036,"askPrice":13.63,"askSize":77,"bidPrice":13.62,"bidSize":533,"shortable":0,"etf":0,"ttmEps":-0.3331,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793583000000},"marketStatusCode":5,"adr":0,"adjPreClose":13.87,"symbolType":"stock","openAndCloseTimeList":[[1793323800000,1793331000000],[1793336400000,1793343600000]],"highLimit":15.26,"lowLimit":12.48,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":504248738,"isCdr":false,"pbRate":0.94,"roa":"--","roe":"0.84%","epsLYR":0.22,"committee":0.608333,"marketValue":6873000000,"turnoverRate":0.0095,"status":1,"floatMarketCap":6873000000},"requestUrl":"/m/hq/s/300294","defaultTab":"news","newsList":[{"id":"2679979222","title":"博雅生物（300294）2026年三季报简析：净利润同比下降81.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679979222","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679979222?lang=zh_cn&edition=full","pubTime":"2026-10-31 11:51","pubTimestamp":1793418707,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期博雅生物发布2026年三季报。根据财报显示，博雅生物净利润同比下降81.82%。截至本报告期末，公司营业总收入8.47亿元，同比下降42.54%，归母净利润6233.73万元，同比下降81.82%。按单季度数据看，第三季度营业总收入2.03亿元，同比下降56.37%，第三季度归母净利润1114.86万元，同比下降90.52%。去年的净利率为5.47%，算上全部成本后，公司产品或服务的附加值一般。本文数据来源于博雅生物2026年三季报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103100025471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679621377","title":"博雅生物(300294)10月9日股东户数3.22万户，较上期减少0.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679621377","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679621377?lang=zh_cn&edition=full","pubTime":"2026-10-30 19:26","pubTimestamp":1793359567,"startTime":"0","endTime":"0","summary":"证券之星消息，近日博雅生物披露，截至2026年10月9日公司股东户数为3.22万户，较9月30日减少164.0户，减幅为0.51%。在生物制品行业个股中，博雅生物股东户数低于行业平均水平，截至10月9日，生物制品行业平均股东户数为3.67万户。从股价来看，2026年9月30日至2026年10月9日，博雅生物区间跌幅为0.4%，在此期间股东户数减少164.0户，减幅为0.51%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000047797.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0197","300294","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679723857","title":"图解博雅生物三季报：第三季度单季净利润同比下降90.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679723857","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679723857?lang=zh_cn&edition=full","pubTime":"2026-10-30 02:34","pubTimestamp":1793298842,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物2026年三季报显示，前三季度公司主营收入8.47亿元，同比下降42.54%；归母净利润6233.73万元，同比下降81.82%；扣非净利润3013.68万元，同比下降85.64%；其中2026年第三季度，公司单季度主营收入2.03亿元，同比下降56.37%；单季度归母净利润1114.86万元，同比下降90.52%；单季度扣非净利润1298.55万元，同比下降70.72%；负债率9.71%，投资收益-3210.52万元，财务费用-2353.63万元，毛利率42.97%。财报数据概要请见下图:本文数据来源于博雅生物2026年三季报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000005433.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679384479","title":"华润医药：华润博雅生物前三季度净利润6058.83万元 同比减少82.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679384479","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679384479?lang=zh_cn&edition=full","pubTime":"2026-10-29 17:22","pubTimestamp":1793265720,"startTime":"0","endTime":"0","summary":"华润医药(03320)发布公告，华润博雅生物于截至2026年9月30日止9个月取得营业总收入人民币8.47亿元(单位下同)，同比减少42.54%;净利润6058.83万元，同比减少82.34%。 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261029/c681248461.shtml","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261029/c681248461.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678121718","title":"博雅生物：重点聚焦流程优化、费用管控、提升组织运营效率等推进降本增效落地落实","url":"https://stock-news.laohu8.com/highlight/detail?id=2678121718","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678121718?lang=zh_cn&edition=full","pubTime":"2026-10-27 16:48","pubTimestamp":1793090896,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)10月27日在投资者关系平台上答复投资者关心的问题。投资者提问：公司现在all in血制品业务，没看到好结果，现在公司都破净了，公司采取了哪些具体的降本增效和应对措施？公司的主业不景气，未来是否考虑开展新业务？博雅生物回复：您好，感谢您对本公司的关注。公司重点聚焦流程优化、费用管控、提升组织运营效率等推进降本增效落地落实。公司将持续深化战略实现途径，围绕营销、研发、国际化、采浆等方面细化关键举措，致力于成为国内乃至世界一流血液制品企业。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700031473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0197","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678131883","title":"股市必读：博雅生物（300294）10月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2678131883","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678131883?lang=zh_cn&edition=full","pubTime":"2026-10-26 05:44","pubTimestamp":1792964653,"startTime":"0","endTime":"0","summary":"截至2026年10月23日收盘，博雅生物报收于14.03元，上涨1.74%，换手率1.36%，成交量6.88万手，成交额9461.89万元。董秘最新回复投资者： 请问未来华润是否有可能出让博雅生物股份，或者出售公司董秘： 您好，感谢您对本公司的关注。公司将持续做好生产经营工作，相关信息请以公司公告为准。当日关注点交易信息汇总：10月23日主力资金净流出293.77万元，占总成交额3.1%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600001443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","300294","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677947210","title":"博雅生物：公司系华润集团大健康板块的血液制品平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2677947210","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677947210?lang=zh_cn&edition=full","pubTime":"2026-10-23 17:24","pubTimestamp":1792747447,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)10月23日在投资者关系平台上答复投资者关心的问题。投资者提问：请问未来华润是否有可能出让博雅生物股份，或者出售公司博雅生物回复：您好，感谢您对本公司的关注。公司系华润集团大健康板块的血液制品平台，始终围绕战略目标，持续聚焦营销、研发、国际化、采浆等方面细化关键举措，聚力夯实主业基本面，提升经营质量与内在价值。公司将持续做好生产经营工作，相关信息请以公司公告为准。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300031546.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0239","BK0046","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677391613","title":"股市必读：博雅生物（300294）10月20日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2677391613","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677391613?lang=zh_cn&edition=full","pubTime":"2026-10-21 02:07","pubTimestamp":1792519631,"startTime":"0","endTime":"0","summary":"截至2026年10月20日收盘，博雅生物报收于14.2元，下跌0.77%，换手率0.8%，成交量4.05万手，成交额5732.73万元。董秘最新回复投资者： 自2025年以来，深市生物医药板块回购增持活跃，同行业公司以真金白银维护价值。二级市场股票价格受到宏观环境、行业政策、投资者风险偏好等因素影响。当日关注点交易信息汇总：10月20日主力资金净流出475.59万元，占总成交额8.3%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100001693.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0046","BK0239","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676661181","title":"博雅生物：持续聚焦营销、研发、国际化、采浆等方面细化关键举措","url":"https://stock-news.laohu8.com/highlight/detail?id=2676661181","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676661181?lang=zh_cn&edition=full","pubTime":"2026-10-20 17:45","pubTimestamp":1792489511,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物10月20日在投资者关系平台上答复投资者关心的问题。公司持续聚焦营销、研发、国际化、采浆等方面细化关键举措，聚力夯实主业基本面，提升经营质量与内在价值。公司将持续做好生产经营工作，相关信息请以公司公告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102000027165.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","300294","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676357361","title":"股市必读：博雅生物（300294）10月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2676357361","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676357361?lang=zh_cn&edition=full","pubTime":"2026-10-19 03:09","pubTimestamp":1792350550,"startTime":"0","endTime":"0","summary":"截至2026年10月16日收盘，博雅生物报收于14.03元，下跌0.85%，换手率1.07%，成交量5.37万手，成交额7644.24万元。董秘最新回复投资者： 鉴于公司目前情况，建议华润无偿转让部分股权给中国生物。经查询中国证券登记结算有限责任公司的数据，公司2026年10月09日含信用账户合并名册的股东人数为32,186户。当日关注点交易信息汇总：10月16日主力资金净流入274.93万元，占总成交额3.6%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900000962.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","300294","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675593209","title":"博雅生物：公司不存在上述事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2675593209","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675593209?lang=zh_cn&edition=full","pubTime":"2026-10-16 18:00","pubTimestamp":1792144843,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)10月16日在投资者关系平台上答复投资者关心的问题。投资者提问：请问国药或者中国生物等业内一线企业，是否有表示过收购博雅的意向？博雅生物回复：您好，感谢您对本公司的关注。公司不存在上述事项。控股股东在战略管理、组织优化、人才引进、风险管理及政府资源的嫁接等各方面，给予了公司极大的支持与赋能，为公司长远、稳定发展奠定了坚实的基础。公司持续深化战略实现途径，围绕营销、研发、国际化、采浆等方面细化关键举措，致力于成为国内乃至世界一流血液制品企业。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600031187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0046","BK0197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675406593","title":"博雅生物：公司2026年10月09日含信用账户合并名册的股东人数为32,186户","url":"https://stock-news.laohu8.com/highlight/detail?id=2675406593","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675406593?lang=zh_cn&edition=full","pubTime":"2026-10-16 18:00","pubTimestamp":1792144843,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)10月16日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止2026年10月10日公司的股东人数是多少？谢谢博雅生物回复：您好，感谢您对本公司的关注。经查询中国证券登记结算有限责任公司的数据，公司2026年10月09日含信用账户合并名册的股东人数为32,186户。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600031185.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300294","BK0197","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674846388","title":"股市必读：博雅生物新发布《公司第八届董事会第二十三次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674846388","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674846388?lang=zh_cn&edition=full","pubTime":"2026-10-12 03:18","pubTimestamp":1791746290,"startTime":"0","endTime":"0","summary":"公司公告汇总公司第八届董事会第二十三次会议决议公告华润博雅生物制药集团股份有限公司于2026年10月8日召开第八届董事会第二十三次会议，审议通过《关于补选第八届董事会非独立董事的议案》，同意补选李宁女士为非独立董事候选人，该事项尚需提交公司2026年第三次临时股东会审议；同时审议通过《关于提请召开公司2026年第三次临时股东会的议案》，临时股东会定于2026年10月29日召开，股权登记日为2026年10月22日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200001051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","300294","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674279004","title":"股市必读：博雅生物新发布《公司第八届董事会第二十三次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674279004","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674279004?lang=zh_cn&edition=full","pubTime":"2026-10-09 02:12","pubTimestamp":1791483134,"startTime":"0","endTime":"0","summary":"公司公告汇总公司第八届董事会第二十三次会议决议公告华润博雅生物制药集团股份有限公司于2026年10月8日召开第八届董事会第二十三次会议，审议通过《关于补选第八届董事会非独立董事的议案》，同意补选李宁女士为非独立董事候选人，该事项尚需提交公司2026年第三次临时股东会审议；同时审议通过《关于提请召开公司2026年第三次临时股东会的议案》，会议定于2026年10月29日召开，股权登记日为2026年10月22日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900002149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","300294","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673003013","title":"博雅生物（300294）披露召开2026年第三次临时股东会的通知，10月08日股价下跌1.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673003013","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673003013?lang=zh_cn&edition=full","pubTime":"2026-10-08 22:32","pubTimestamp":1791469937,"startTime":"0","endTime":"0","summary":"截至2026年10月8日收盘，博雅生物报收于14.66元，较前一交易日下跌1.87%，最新总市值为73.92亿元。近日，华润博雅生物制药集团股份有限公司发布《关于召开公司2026年第三次临时股东会的通知》。公告显示，公司将于2026年10月29日召开2026年第三次临时股东会，会议由公司董事会召集，采取现场投票与网络投票相结合的方式。股权登记日为2026年10月22日，审议事项包括补选第八届董事会非独立董事。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800034678.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0197","300294","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671542272","title":"博雅生物：公司持续深化战略实现途径","url":"https://stock-news.laohu8.com/highlight/detail?id=2671542272","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671542272?lang=zh_cn&edition=full","pubTime":"2026-09-30 16:51","pubTimestamp":1790758286,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)09月30日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司认为股价持续低迷的原因是什么？对此公司具体采取了什么措施？博雅生物回复：您好，感谢您对本公司的关注。公司股价受宏观经济、行业政策、市场环境等多重因素影响，敬请投资者理性看待市场波动，审慎决策，注意投资风险。公司持续深化战略实现途径，围绕营销、研发、国际化、采浆等方面细化关键举措，坚持以深耕主业、提升盈利质量夯实内在价值根基，同时严格履行信息披露义务。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000026345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","300294","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671272544","title":"博雅生物：致力于成为国内乃至世界一流血液制品企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2671272544","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671272544?lang=zh_cn&edition=full","pubTime":"2026-09-30 16:51","pubTimestamp":1790758277,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)09月30日在投资者关系平台上答复投资者关心的问题。投资者提问：公司是否有考虑将博雅转让给更懂得经营它的平台运营，如中国生物，如海尔集团博雅生物回复：您好，感谢您对本公司的关注。控股股东在战略管理、组织优化、人才引进、风险管理及政府资源的嫁接等各方面，给予了公司极大的支持与赋能，为公司长远、稳定发展奠定了坚实的基础。公司持续深化战略实现途径，围绕营销、研发、国际化、采浆等方面细化关键举措，致力于成为国内乃至世界一流血液制品企业。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000026342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0239","BK0197","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669143878","title":"股市必读：博雅生物（300294）9月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2669143878","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669143878?lang=zh_cn&edition=full","pubTime":"2026-09-24 01:46","pubTimestamp":1790185577,"startTime":"0","endTime":"0","summary":"截至2026年9月23日收盘，博雅生物报收于14.72元，下跌0.94%，换手率0.73%，成交量3.68万手，成交额5473.38万元。董秘最新回复投资者： 贵公司对于市值管理有什么优秀经验，可以跟股东分享一下吗？公司股价受宏观经济、行业政策、市场环境等多重因素影响，敬请投资者理性看待市场波动，审慎决策，注意投资风险。当日关注点交易信息汇总：9月23日主力资金净流出632.24万元，占总成交额11.55%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400002164.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300294","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669101780","title":"博雅生物：以做优做强主业、提升经营质量作为市值管理的核心措施","url":"https://stock-news.laohu8.com/highlight/detail?id=2669101780","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669101780?lang=zh_cn&edition=full","pubTime":"2026-09-23 17:15","pubTimestamp":1790154923,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)09月23日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司对于市值管理有什么优秀经验，可以跟股东分享一下吗？博雅生物回复：您好，感谢您对本公司的关注。公司股价受宏观经济、行业政策、市场环境等多重因素影响，敬请投资者理性看待市场波动，审慎决策，注意投资风险。公司将市值管理作为一项长期性、系统性、战略性工作持续推进，以做优做强主业、提升经营质量作为市值管理的核心措施，促进公司健康可持续发展。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300029282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0046","BK0197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668925061","title":"博雅生物：截至目前，公司暂无回购、大股东增持等事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2668925061","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668925061?lang=zh_cn&edition=full","pubTime":"2026-09-18 20:51","pubTimestamp":1789735907,"startTime":"0","endTime":"0","summary":"另外十七条还规定“市值形势持续低迷时，采取回购、大股东增持等方式，增强投资者信心，维护市值稳定”，请问公司如何定义“持续低迷”?当下公司股价连续下跌若干年，股价破净，请问是否符合公司定义的“持续低迷”？截至目前，公司暂无回购、大股东增持等事项，后续如有相关安排，公司将严格按照规定履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091800035040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","300294","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793434048279,"stockEarnings":[{"period":"1week","weight":-0.0285},{"period":"1month","weight":-0.0877},{"period":"3month","weight":-0.1274},{"period":"6month","weight":-0.2168},{"period":"1year","weight":-0.4497},{"period":"ytd","weight":-0.3942}],"compareEarnings":[{"period":"1week","weight":-0.0248},{"period":"1month","weight":-0.0633},{"period":"3month","weight":-0.0609},{"period":"6month","weight":-0.1248},{"period":"1year","weight":-0.0973},{"period":"ytd","weight":-0.0932}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华润博雅生物制药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"32186人(较上一季度减少0.51%)","perCapita":"15666股","listingDate":"2012-03-08","address":"江西省抚州市临川区高新技术产业开发区惠泉路333号","registeredCapital":"50424万元","survey":" 华润博雅生物制药集团股份有限公司的主营业务是血液制品的研发、生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白（pH4）、凝血因子。公司获得了国家“863计划”项目、江西省重大研发专项等20多项政府专项，拥有各类专利200余项，多次荣膺省、市科学技术奖和优秀新产品奖。","listedPrice":25},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博雅生物,300294,博雅生物股票,博雅生物股票老虎,博雅生物股票老虎国际,博雅生物行情,博雅生物股票行情,博雅生物股价,博雅生物股市,博雅生物股票价格,博雅生物股票交易,博雅生物股票购买,博雅生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}